1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics 2020 - European Union (p5)

Cancer Analysis & Statistics 2020 - European Union (p5)

Customer Support

Talk to Ahmad

+1 718 618 4302

All regions

121-135 of about 100 reports

Head and neck cancer

  • $ 5000
  • June 2016
  • 208 pages

Revenues from new brands will offset the biosimilar and generic erosion of Erbitux and TS-1, enabling the net growth of the head and neck cancer market. This report addresses the following questions: ...

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Hospital
  • Therapy
  • European Union

Breast cancer: triple - negative

  • $ 5000
  • May 2016
  • 290 pages

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need. This report addresses the following ...

  • Cancer
  • European Union
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • TESARO, Inc.

NHL: Diffuse large Bcell lymphoma

  • $ 5000
  • May 2016
  • 219 pages

An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016–25 ...

  • Cancer
  • European Union
  • Japan
  • Celgene Corporation
  • Roche Group

Chronic myeloid leukemia

  • $ 5000
  • May 2016
  • 219 pages

Sprycel and Tasigna continue to compete for market share in second-line CML as generic imatinib begins to supersede Gleevec in all markets. This report addresses the following questions: - What are ...

  • Cancer
  • European Union
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

NHL: Mantle cell lymphoma

  • $ 5000
  • April 2016
  • 214 pages

An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016–25. This ...

  • Cancer
  • European Union
  • Celgene Corporation
  • Pfizer Inc.
  • Roche Group

Breast cancer: HR+/HER2-

  • $ 5000
  • April 2016
  • 273 pages

Ibrance’s continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market. This report addresses the following questions: - Which branded ...

  • Breast Cancer
  • Cancer
  • European Union
  • GlaxoSmithKline plc
  • Roche Group

Hepatocellular cancer

  • $ 5000
  • April 2016
  • 216 pages

The success of Nexavar has boosted the development of new targeted therapies, approvals of which will drive the growth of the hepatocellular cancer market. This report addresses the following questions: - ...

  • Cancer
  • European Union
  • ArQule, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly & Co.

Renal cell cancer

  • $ 5000
  • April 2016
  • 283 pages

Despite the approvals of several pipeline therapies, the renal cell cancer (RCC) market is expected to experience only moderate growth due to market saturation and the expiries of key brand patents. This ...

  • Cancer
  • European Union
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

NHL: Follicular lymphoma

  • $ 5000
  • April 2016
  • 252 pages

The follicular lymphoma (FL) market will continue to grow during 2016–25, despite the entry of biosimilars and generics, due to an increase in disease incidence and the launch of new pipeline therapies. This ...

  • Cancer
  • European Union
  • Biogen Idec Inc.
  • Gilead Sciences, Inc.
  • Roche Group

Acute lymphoblastic leukemia

  • $ 5000
  • April 2016
  • 193 pages

The entry of CAR-T therapies will offset the generic erosion of the TKI class to drive huge growth in the acute lymphoblastic leukemia (ALL) market. This report addresses the following questions: - In ...

  • Cancer
  • European Union
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.

Pancreatic cancer

  • $ 5000
  • April 2016
  • 180 pages

The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies. This report addresses the ...

  • Cancer
  • European Union
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Taiho Pharmaceutical Co., Ltd.

Colorectal cancer

  • $ 5000
  • April 2016
  • 402 pages

Pipeline candidates for the colorectal cancer market will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market. This report addresses the following questions: ...

  • Cancer
  • European Union
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

Chemotherapy induced anemia

  • $ 5000
  • April 2016
  • 176 pages

The chemotherapy-induced anemia (CIA) market is expected to grow marginally due to a lack of novel therapies and a static disease population. This report addresses the following questions: - How have ...

  • Cancer
  • European Union
  • Japan
  • Amgen Inc.
  • Galenica Group

Prostate cancer

  • $ 5000
  • February 2016
  • 354 pages

The value of the prostate cancer market will more than double during 2015–24, reaching $13.5bn in 2024 at a compound annual growth rate (CAGR) of 8.6%. This report addresses the following questions: - ...

  • Cancer
  • European Union
  • PROVENGE group
  • Sanofi S.A.
  • Valeant Pharmaceuticals International, Inc.

Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

  • $ 1077
  • January 2016
  • 1 pages

Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) ...

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy
  • European Union

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on